PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025

(2017) Bernard Escudier et al.   EUROPEAN UROLOGY

Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy

(2017) Leslie S. Kean et al.   IMMUNOLOGICAL REVIEWS

Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.

(2017) Ignacio Melero et al.   JOURNAL OF CLINICAL ONCOLOGY

Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial

(2017) Marc P.E. André et al.   JOURNAL OF CLINICAL ONCOLOGY

Homologous recombination deficiency (HRD) in patients with pancreatic cancer (PC) and response to chemotherapy.

(2017) Safi Shahda et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.

(2017) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts.

(2017) Zev A. Wainberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.

(2017) Yoon-Koo Kang et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress

(2017) Zin W. Myint et al.   Journal of Hematology & Oncology

Clinical applications of PD-L1 bioassays for cancer immunotherapy

(2017) Delong Liu et al.   Journal of Hematology & Oncology

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

(2017) Toshihiro Kudo et al.   LANCET ONCOLOGY

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

(2017) Van K Morris et al.   LANCET ONCOLOGY

Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials

(2017) Masatoshi Kudo   ONCOLOGY

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma

(2017) Hae Il Jung et al.   Cancer Research and Treatment

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade

(2017) Pornpimol Charoentong et al.   Cell Reports

Association of primary tumor lymph node ratio with burden of liver metastases and survival in stage IV colorectal cancer

(2017) Ali Ahmad et al.   HEPATOBILIARY SURGERY AND NUTRITION

Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability

(2016) Changqing Ma et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Chemotherapy remains an essential element of personalized care for persons with lung cancers

(2016) M. D. Hellmann et al.   ANNALS OF ONCOLOGY

Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma

(2016) Faiz Gani et al.   ANNALS OF SURGICAL ONCOLOGY

Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy

(2016) Xiaohong Wang et al.   CANCER RESEARCH

Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges

(2016) Francesca Tartari et al.   CANCER TREATMENT REVIEWS

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

(2016) Stéphane Champiat et al.   CLINICAL CANCER RESEARCH

Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy

(2016) Gautam Kishore Valecha et al.   Expert Review of Anticancer Therapy

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

(2016) Antoni Ribas et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lapatinib in Gastric Cancer: What Is the LOGiCal Next Step?

(2016) Yelena Y. Janjigian   JOURNAL OF CLINICAL ONCOLOGY

Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.

(2016) Hyun Cheol Chung et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of nivolumab (ONO-4538/BMS-936558) in patients with esophageal cancer: Preliminary report of overall survival.

(2016) Takashi Kojima et al.   JOURNAL OF CLINICAL ONCOLOGY

Change in Pattern ofHER2Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines

(2016) Mithun Vinod Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475).

(2016) Toshihiko Doi et al.   JOURNAL OF CLINICAL ONCOLOGY

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing

(2016) Klazien Matter-Walstra et al.   Journal of Thoracic Oncology

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

(2016) Kei Muro et al.   LANCET ONCOLOGY

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

(2016) Geoffrey T Gibney et al.   LANCET ONCOLOGY

Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein–Barr virus-associated gastric cancer: the prognostic implications

(2016) Ruri Saito et al.   MODERN PATHOLOGY

A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns

(2016) Faiyaz Notta et al.   NATURE

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy

(2016) Wang Jing et al.   OncoTargets and Therapy

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

(2016) Douglas B. Johnson et al.   Nature Communications

Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review

(2016) Jung Han Kim   Oncotarget

Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers

(2016) Sarah Derks et al.   Oncotarget

The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients

(2016) Minghui Zhang et al.   Scientific Reports

Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers

(2016) Jung Hoon Kim et al.   Journal of Cancer

Recent developments in the use of immunotherapy in non-small cell lung cancer

(2016) Mariacarmela Santarpia et al.   Expert Review of Respiratory Medicine

Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy

(2016) Kristina H. Young et al.   PLoS One

Immunotherapy in hepatocellular carcinoma: Primed to make a difference?

(2015) James J. Harding et al.   CANCER

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites

(2015) H. M. Kluger et al.   CLINICAL CANCER RESEARCH

500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028

(2015) P.A. Ott et al.   EUROPEAN JOURNAL OF CANCER

525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028

(2015) Y.J. Bang et al.   EUROPEAN JOURNAL OF CANCER

Tumor neoantigens: building a framework for personalized cancer immunotherapy

(2015) Matthew M. Gubin et al.   JOURNAL OF CLINICAL INVESTIGATION

PD-1 blockade in tumors with mismatch repair deficiency.

(2015) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.

(2015) Anthony B. El-Khoueiry et al.   JOURNAL OF CLINICAL ONCOLOGY

Pseudoprogression and Immune-Related Response in Solid Tumors

(2015) Victoria L. Chiou et al.   JOURNAL OF CLINICAL ONCOLOGY

Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?

(2015) Andy Yingjie Lin et al.   Journal of Hematology & Oncology

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

A New Initiative on Precision Medicine

(2015) Francis S. Collins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

(2015) Krzysztof M. Zak et al.   STRUCTURE

Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma—An exclamation sign with a question mark

(2015) Guido Kroemer et al.   OncoImmunology

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2015) et al.   JOURNAL OF HEPATOLOGY

The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review

(2014) Zhi Ven Fong et al.   CANCER

The PD-1/PD-Ls pathway and autoimmune diseases

(2014) Suya Dai et al.   CELLULAR IMMUNOLOGY

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Microsatellite Instability Detection by Next Generation Sequencing

(2014) S. J. Salipante et al.   CLINICAL CHEMISTRY

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Cutting Edge: Self-Antigen Controls the Balance between Effector and Regulatory T Cells in Peripheral Tissues

(2014) I. K. Gratz et al.   JOURNAL OF IMMUNOLOGY

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold

(2014) Peter J. Neumann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

(2014) F. S. Hodi et al.   Cancer Immunology Research

Exomics and immunogenics

(2014) Stéphane Champiat et al.   OncoImmunology

Squamous anal cancer: Patient characteristics and HPV type distribution

(2013) N. Ouhoummane et al.   Cancer Epidemiology

Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy

(2013) Alexandr V. Bazhin et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity

(2013) Mei-Ling Chen et al.   INTERNATIONAL JOURNAL OF CANCER

Oesophageal carcinoma

(2013) Arjun Pennathur et al.   LANCET

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Understanding immunosenescence to improve responses to vaccines

(2013) Jörg J Goronzy et al.   NATURE IMMUNOLOGY

Advances in targeting cell surface signalling molecules for immune modulation

(2013) Sheng Yao et al.   NATURE REVIEWS DRUG DISCOVERY

Therapeutic Implications of KIT in Melanoma

(2012) Michael A. Postow et al.   CANCER JOURNAL

From tumor cell metabolism to tumor immune escape

(2012) Martin Villalba et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of stroma in pancreatic cancer: diagnostic and therapeutic implications

(2012) Mert Erkan et al.   Nature Reviews Gastroenterology & Hepatology

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunological and Molecular Correlates of Disease Recurrence after Liver Resection for Hepatocellular Carcinoma

(2012) Elisabetta Cariani et al.   PLoS One

Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2--Tumor and Immunological Responses

(2012) S. K. Seung et al.   Science Translational Medicine

Innate immunosenescence: Effect of aging on cells and receptors of the innate immune system in humans

(2012) Rafael Solana et al.   SEMINARS IN IMMUNOLOGY

TOR in the immune system

(2011) Koichi Araki et al.   CURRENT OPINION IN CELL BIOLOGY

Regulatory T Cells Require Mammalian Target of Rapamycin Signaling To Maintain Both Homeostasis and Alloantigen-Driven Proliferation in Lymphocyte-Replete Mice

(2011) Y. Wang et al.   JOURNAL OF IMMUNOLOGY

Hepatocellular Carcinoma

(2011) Hashem B. El-Serag   NEW ENGLAND JOURNAL OF MEDICINE

HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia

(2011) Joel M. Palefsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma

(2011) Zhen Zeng et al.   PLoS One

Timing Is Critical for an Effective Anti-Metastatic Immunotherapy: The Decisive Role of IFNγ/STAT1-Mediated Activation of Autophagy

(2011) Jun Yan et al.   PLoS One

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma

(2011) Bao-Ju Wang   WORLD JOURNAL OF GASTROENTEROLOGY

An Oscillatory Switch in mTOR Kinase Activity Sets Regulatory T Cell Responsiveness

(2010) Claudio Procaccini et al.   IMMUNITY

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

(2010) Richard E. Royal et al.   JOURNAL OF IMMUNOTHERAPY

Mismatch repair deficient colorectal cancer in the era of personalized treatment

(2010) Madeleine Hewish et al.   Nature Reviews Clinical Oncology

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

(2009) Q. Gao et al.   CLINICAL CANCER RESEARCH

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1

(2009) Dong-Ming Kuang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion

(2009) Yufu Ye et al.   JOURNAL OF SURGICAL ONCOLOGY

Systemic effects of local radiotherapy

(2009) Silvia C Formenti et al.   LANCET ONCOLOGY

Epitope Landscape in Breast and Colorectal Cancer

(2008) N. H. Segal et al.   CANCER RESEARCH